Thymoma
60
9
15
23
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
11 trials with published results (18%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.0%
6 terminated out of 60 trials
79.3%
-7.2% vs benchmark
3%
2 trials in Phase 3/4
48%
11 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (60)
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG
Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Molecular Analysis of Thoracic Malignancies
SP Thoracic IDE Study
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers